Skip to main content

ETHNOS_APP

Home • Search • Journals • List 0

Budgetary impact of diagnostic tests for visceral leishmaniasis in Brazil

Bibliographic Data

ID5167878
AuthorsTália Santana Machado De Assis (0000-0002-5682-2981, Centro Federal de Educação Tecnológica de Minas Gerais, Brazil; Fundação Oswaldo Cruz, Brazil), André Luís Ferreira De Azeredo-Da-Silva (Instituto para Avaliação de Tecnologias em Saúde, Brasil; Universidade Federal do Rio Grande do Sul, Brazil), Diana Oliveira (0000-0002-5434-1818, Fundação Oswaldo Cruz), Gina Cota (0000-0003-0538-7403, Fundação Oswaldo Cruz), Gláucia Cota (Fundação Oswaldo Cruz), Guilherme Loureiro Werneck (0000-0003-1169-1436, Universidade do Estado do Rio de Janeiro), Ana Rabello (0000-0001-5821-4069, Fundação Oswaldo Cruz)
Year2017
Volume33
Issue12
Pagese00142416-e00142416
Publication date2017-12-18
Peer ReviewedYes
Open AccessYes
TypeARTICLE
VenueCadernos de Saude Publica (JOURNAL)
Journal identifiersISSN: 0102-311X • E-ISSN: 1678-4464
PublisherFapUNIFESP (SciELO) (PUBLISHER)
DOI10.1590/0102-311x00142416
PMID29267689
OpenAlexW2771995592
SCIELO_PIDS0102-311X2017001205013
LanguageEN
References cited13

The aim of the present study was to estimate the financial costs of the incorporation and/or replacement of diagnostic tests for human visceral leishmaniasis (VL) in Brazil. The analysis was conducted from the perspective of the Brazilian Unified National Health System (SUS) over a period of three years. Six diagnostic tests were evaluated: the indirect immunofluorescence antibody test (IFAT), the IT LEISH rapid test, the parasitological examination of bone marrow aspirate, the direct agglutination test (DAT-LPC) standardized in the Clinical Research Laboratory, René Rachou Institute of the Oswaldo Cruz Foundation, the Kalazar Detect rapid test, and polymerase chain reaction (PCR). The assumptions used were the number of suspected cases of VL reported to the Brazilian Ministry of Health in 2014 and the direct cost of diagnostic tests. The costs to diagnose suspected cases of VL over three years using the IFAT and the DAT-LPC were estimated at USD 280,979.91 and USD 121,371.48, respectively. The analysis indicated that compared with the use of the IFAT, the incorporation of the DAT-LPC into the SUS would result in savings of USD 159,608.43. With regard to the budgetary impact of rapid tests, the use of IT LEISH resulted in savings of USD 21.708,72 over three years. Compared with a parasitological examination, diagnosis using PCR resulted in savings of USD 3,125,068.92 over three years. In this study, the replacement of the IFAT with the DAT-LPC proved financially advantageous. In addition, the replacement of the Kalazar Detect rapid test with the IT LEISH in 2015 was economically valuable, and the replacement of parasitological examination with PCR was indicated

Antibody · Christian ministry · Diagnostic test · Direct agglutination test · Direct examination · Indirect immunofluorescence · Leishmaniasis · Pathology · Serology · Veterinary medicine · Visceral leishmaniasis · Immunology · Internal Medicine · Medicine · Research on Leishmaniasis Studies

  • Diretriz para análises de impacto orçamentário de tecnologias em saúde no Brasil

    Open Access•Andre Luis Ferreira-Da-Silva, Rodrigo Antonini Ribeiro et al.•Cadernos de Saude Publica•2012

  • Avaliação econômica em saúde

    Open Access•Tazio Vanni, Paula M Luz et al.•Cadernos de Saude Publica•2009

Citation velocityhistorical
Highly citedNo

Tools

Open DOISci-HubOpen Access
Ethnos_APP • Open Source Project • MIT License • Frontend v2.0.0 • Privacy and Cookies • API Documentation: api.ethnos.app/docs • API Source Code: GitHub • DOI: 10.5281/zenodo.17049435 • Frontend Source Code: GitHub • DOI: 10.5281/zenodo.17050053 • cruz.rio.br • Expectantes Misericordiae